Hutchison China MediTech Ltd (HCM.OQ)

HCM.OQ on NASDAQ Stock Exchange Global Select Market

9:55pm IST
Change (% chg)

$-0.06 (-0.17%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the... (more)


No Ratios Available.


  Industry Sector
P/E (TTM): -- 31.15 16.44
EPS (TTM): -- -- --
ROI: -- 14.99 10.62
ROE: -- 16.33 14.20

China cancer specialist Chi-Med plans $262 mln share offering

LONDON, Oct 25 China-based cancer and immunology drug specialist Hutchison China MediTech, or Chi-Med, said it aimed to offer $262 million of American Depositary Shares, subject to market conditions, to help fund development of its pipeline.

25 Oct 2017

BRIEF-Astrazeneca says co and Chi-med's Savolitinib shows encouraging clinical activity

* Astrazeneca and Chi-med’s Savolitinib shows encouraging clinical activity in 2nd-line EGFR mutation-positive lung cancer with met-amplification

17 Oct 2017

UPDATE 1-Celgene signs deal with BeiGene for tumor cancer treatment

July 6 Celgene Corp said it would buy a stake in BeiGene Ltd to help develop and commercialize the China-based cancer immunotherapy developer's treatment for solid tumor cancers, expanding its position in the field of immuno-oncology.

06 Jul 2017

Chi-Med steps closer to Chinese pharma first with drug filing

(This story corrects to remove reference to Lilly in paragraph 4.)

13 Jun 2017

CORRECTED-Chi-Med steps closer to Chinese pharma first with drug filing

LONDON, June 12 Hutchison China MediTech , the Shanghai-based drugmaker listed in London, is a step closer to winning approval for a modern drug developed in a Chinese lab with the submission of its cancer medicine fruquintinib to China's drug watchdog.

13 Jun 2017

Earnings vs. Estimates